Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

Sponsor
Ulrik Lassen
Study ID
NCT03890952
Phase
PHASE2
Status
Completed

Conditions

  • Recurrent Adult Brain Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
  • Bevacizumab — DRUG
    Treatment with the combination of Nivolumab and bevacizumab every 2 weeks

Study Details

The aim of this study is to make preliminary assessment of PD-L1 and other immune related biomarkers that might act as predictors of anti-tumor activity of Nivolumab in patients with recurrent glioblastoma

Key Dates

Start date
Oct 1, 2018
Status verified
Jul 2025
Primary completion
Feb 1, 2023
Completion
Aug 1, 2024

Study Design

Enrollment
40 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Arm B Nivolumab and bevacizumab
    Nivolumab and bevacizumab in patients not undergoing salvage surgery
  • Experimental: Arm A Nivolumab and bevacizumab
    Nivolumab and bevacizumab in patients undergoing salvage surgery

Primary Outcome Measure

Number of indels as determined using mRNA sequencing [ Time Frame: 8 weeks ]

Related Studies